Cancer Therapies: Technologies and Global Markets

Table of Contents

• Cancer Therapies: Technologies and Global Markets

Chapter- 1: SUMMARY

• SUMMARY TABLE THE GLOBAL CANCER THERAPY MARKET, THROUGH 2013 ($ MILLIONS)
• SUMMARY FIGURE THE GLOBAL CANCER THERAPY MARKET, 2006-2013 ($ MILLIONS)

Chapter- 2: OVERVIEW

• WHAT IS CANCER?
• CAUSES OF CANCER
• TYPES OF CANCER
• BLADDER CANCER
• Risk Factors
• Treatment
• BREAST CANCER
• Risk Factors
• Treatment
• Treatment (continued)
• COLORECTAL CANCER
• Risk Factors
• Treatment
• ENDOMETRIAL CANCER
• Risk Factors
• Treatment
• KIDNEY CANCER
• Risk Factors
• Treatment
• LEUKEMIA
• Risk Factors
• Treatment
• LUNG CANCER
• Risk Factors
• Treatment
• MELANOMA
• Risk Factors
• Treatment
• NON-HODGKIN' S LYMPHOMA
• Risk Factors
• Treatment
• PANCREATIC CANCER
• Risk Factors
• Treatment
• PROSTATE CANCER
• Risk Factors
• Treatment
• SKIN CANCER
• Risk Factors
• Treatment
• THYROID CANCER
• Risk Factors
• Treatment
• Treatment (Continued)

Chapter- 3: REGULATORY ISSUES

• NEW DRUG APPROVALS
  • TABLE 1 CANCER DRUGS APPROVED BY THE FDA
  • TABLE 1 (CONTINUED)
  • TABLE 1 (CONTINUED)
  • TABLE 1 (CONTINUED)
  • TABLE 1 (CONTINUED)
  • TABLE 1 (CONTINUED)
  • TABLE 1 (CONTINUED)
  • TABLE 1 (CONTINUED)
• NEW DRUG APPLICATIONS
  • TABLE 2 NEW DRUG APPLICATIONS (2005 TO JANUARY 2008)
• RECALLS
  • TABLE 3 RECALLS (2005 TO JANUARY 2008)
  • TABLE 3 (CONTINUED)
  • TABLE 3 (CONTINUED)

Chapter- 4: PREVALENCE

• WORLDWIDE PREVALENCE
  • TABLE 4 WORLDWIDE PREVALENCE OF CANCER, 2007 (MILLIONS)
  • TABLE 5 WORLDWIDE PREVALENCE OF NEW CASES OF CANCER, BY REGION, 2007
  • TABLE 6 WORLDWIDE DEATHS DUE TO CANCER, BY REGION, 2007
• PREVALENCE IN THE UNITED STATES
  • TABLE 7 ESTIMATED NEW CANCER CASES IN THE U.S., 2007
  • TABLE 8 CANCER DEATHS IN THE U.S., 2007
• PREVALENCE IN EUROPE
  • TABLE 9 ESTIMATED NEW CANCER CASES IN EUROPE, 2007
  • TABLE 10 CANCER DEATHS IN EUROPE, 2007

Chapter- 5: CLASSIFICATION OF CANCER THERAPIES

• CHEMOTHERAPY
• ALKYLATING AND ALKYLATING-LIKE AGENTS
  • TABLE 11 ALKYLATING AGENTS
• ANTIMETABOLITES
  • TABLE 12 ANTIMETABOLITES
• ANTHRACYCLINES
  • TABLE 13 CYTOTOXIC ANTIBIOTIC DRUGS
  • TABLE 13 (CONTINUED)
• PLANT ALKALOIDS
  • TABLE 14 ALKALOIDS/MITOTIC INHIBITORS
• TOPOISOMERASE INHIBITORS
  • TABLE 15 TOPOISOMERASE INHIBITORS
• BIOLOGICAL THERAPY OR IMMUNOTHERAPY
• INTERFERONS AND OTHER CYTOKINES
  • TABLE 16 INTERFERONS USED IN CANCER THERAPY
  • TABLE 17 INTERLEUKINS USED IN CANCER THERAPY
• CANCER VACCINES
• HORMONE THERAPY
• ANTIESTROGENS
  • TABLE 18 ANTIESTROGENS USED IN CANCER THERAPY
• AROMATASE INHIBITOR
  • TABLE 19 AROMATASE INHIBITORS USED IN THE TREATMENT OF CANCER
• ANTIANDROGENS
  • TABLE 20 ANTIANDROGENS USED IN CANCER TREATMENT
• LUTEINIZING HORMONE-RELEASING HORMONE
  • TABLE 21 LUTEINIZING HORMONE-RELEASING HORMONE USED IN THE TREATMENT OF CANCER
• TARGETED THERAPY
• SMALL MOLECULES/CANCER GROWTH INHIBITORS
  • TABLE 22 CANCER GROWTH INHIBITORS
  • TABLE 22 (CONTINUED)
• MONOCLONAL ANTIBODIES
• Conjugated
• Naked
  • TABLE 23 MONOCLONAL ANTIBODIES USED IN THE TREATMENT OF CANCER

Chapter- 6: INDUSTRY STRUCTURE

• CHEMOTHERAPY
• ALKYLATING AGENTS
  • TABLE 24 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ALKYLATING AGENTS, 2007 (%)
  • FIGURE 1 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ALKYLATING AGENTS, 2007 (%)
• ANTHRACYCLINES
  • TABLE 25 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTHRACYCLINES, 2007 (%)
  • FIGURE 2 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTHRACYCLINES, 2007 (%)
• PLANT ALKALOIDS
  • TABLE 26 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR PLANT ALKALOIDS, 2007 (%)
  • FIGURE 3 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR PLANT ALKALOIDS, 2007 (%)
• ANTIMETABOLITES
  • TABLE 27 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIMETABOLITES, 2007 (%)
  • FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIMETABOLITES, 2007 (%)
• TOPOISOMERASE
  • TABLE 28 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TOPOISOMERASE, 2007 (%)
  • FIGURE 5 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TOPOISOMERASE, 2007 (%)
• MARKET LEADERS OF CHEMOTHERAPY
  • TABLE 29 WORLDWIDE MARKET SHARE IN CHEMOTHERAPY, 2007 (%)
  • FIGURE 6 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR CHEMOTHERAPY, 2007 (%)
• HORMONE THERAPY
• ANTIESTROGENS
  • TABLE 30 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIESTROGENS, 2007 (%)
  • FIGURE 7 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIESTROGENS, 2007 (%)
• ANTIANDROGENS
  • TABLE 31 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIANDROGENS, 2007 (%)
  • FIGURE 8 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR ANTIENDROGENS, 2007 (%)
• AROMATASE INHIBITORS
  • TABLE 32 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR AROMATASE INHIBITORS, 2007 (%)
  • FIGURE 9 SHARES OF MANUFCATURERS/DISTRIBUTORS FOR AROMATASE INHIBITOR, 2007 (%)
• LH-RH AGONIST INHIBITORS
  • TABLE 33 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR LH-RH AGONIST INHIBITORS, 2007 (%)
  • FIGURE 10 SHARES OF MANUFACTURERS/ DISTRIBUTORS FOR LH RH AGONIST INHIBITORS, 2007 (%)
• MARKET LEADERS OF HORMONE THERAPY
  • TABLE 34 WORLDWIDE MARKET SHARE IN HORMONE THERAPY, 2007 (%)
  • FIGURE 11 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR HORMONE THERAPY, 2007 (%)
• TARGETED THERAPY
• MONOCLONAL ANTIBODIES
  • TABLE 35 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR MONOCLONAL ANTIBODIES, 2007 (%)
  • FIGURE 12 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR MONOCLONAL ANTIBODIES, 2007 (%)
• SMALL MOLECULES
  • TABLE 36 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR SMALL MOLECULES, 2007 (%)
  • FIGURE 13 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR SMALL MOLECULES, 2007 (%)
• MARKET LEADERS OF TARGET THERAPY
  • TABLE 37 WORLDWIDE MARKET SHARE IN TARGET THERAPY, 2007 (%)
  • FIGURE 14 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR TARGET THERAPY, 2007 (%)
• IMMUNOTHERAPY
• INTERFERON AND CYTOKINES
  • TABLE 38 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR INTERFERONS AND CYTOKINES, 2007 (%)
  • FIGURE 15 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR INTERFERONS AND CYTOKINES, 2007 (%)
• CANCER VACCINES
  • TABLE 39 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR CANCER VACCINES, 2007 (%)
  • FIGURE 16 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR CANCER VACCINES, 2007 (%)
• MARKET LEADERS OF IMMUNOTHERAPY
  • TABLE 40 WORLDWIDE MARKET SHARE IN IMMUNOTHERAPY, 2007 (%)
  • FIGURE 17 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR IMMUNOTHERAPY, 2007 (%)
• DEMAND AND USE
• FACTORS AFFECTING SALES OF CANCER DRUGS
• Competition
• Pricing/Cost
• MAJOR FACTORS FOR FUTURE GROWTH
• Life Expectancy
• Patent Protection
• Drug Portfolio Management
• Significant Potential of Developing Countries
• FUTURE OF THE CANCER MARKET
• Chemotherapy Will Sustain
• Targeted Therapy dominates
• Patent Expiries
• STRATEGIES OF BIG PHARMACEUTICAL COMPANIES
• Enhancement in Production Capacity:
• Market Strategy
• Mergers, Acquisitions, and Collaborations
• Further Investigations

Chapter- 7: MARKET ANALYSIS

• CHEMOTHERAPY
• CHEMOTHERAPY (CONTINUED)
• Market Size
  • TABLE 41 GLOBAL SALES OF DRUGS USED IN CHEMOTHERAPY, THROUGH 2013 ($ MILLIONS)
  • FIGURE 18 GLOBAL SALES OF DRUGS USED IN CHEMOTHERAPY, 2006-2013 ($ MILLIONS)
  • TABLE 42 GLOBAL MARKET SHARE OF CHEMOTHERAPY BY TYPE, 2007 (%)
  • FIGURE 19 GLOBAL MARKET SHARE OF CHEMOTHERAPY BY TYPE, 2007 (%)
• ALKYLATING AGENTS
  • TABLE 43 GLOBAL SALES OF ALKYLATING AGENTS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 20 GLOBAL SALES OF ALKYLATING AGENTS, 2006-2013 ($ MILLIONS)
• ANTHRACYCLINES
  • TABLE 44 GLOBAL SALES OF ANTHRACYCLINES, THROUGH 2013 ($ MILLIONS)
  • FIGURE 21 GLOBAL SALES OF ANTHRACYCLINES, 2006-2013 ($ MILLIONS)
• PLANT ALKALOIDS
  • TABLE 45 GLOBAL SALES OF PLANT ALKALOIDS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 22 GLOBAL SALES OF PLANT ALKALOIDS, 2006-2013 ($ MILLIONS)
• ANTIMETABOLITES
  • TABLE 46 GLOBAL SALES OF ANTIMETABOLITES, THROUGH 2013 ($ MILLIONS)
  • FIGURE 23 GLOBAL SALES OF ANTIMETABOLITES, 2006-2013 ($ MILLIONS)
• TOPOISOMERASE INHIBITORS
  • TABLE 47 GLOBAL SALES OF TOPOISOMERASE INHIBITORS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 24 GLOBAL SALES OF TOPISOMERASE INHIBITORS, 2006-2013 ($ MILLIONS)
• HORMONE THERAPY
• Market Size
  • TABLE 48 GLOBAL SALES OF HORMONE THERAPIES, THROUGH 2013 ($ MILLIONS)
  • FIGURE 25 GLOBAL SALES OF HORMONE THERAPIES, 2006-2013 ($ MILLIONS)
  • TABLE 49 GLOBAL SHARE OF HORMONE THERAPY, BY TYPE, 2007 (%)
  • FIGURE 26 GLOBAL SHARE OF HORMONE THERAPY, BY TYPE, 2007 (%)
• ANTIESTROGENS
  • TABLE 50 GLOBAL SALES OF ANTIESTROGENS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 27 GLOBAL SALES OF ANTIESTROGENS, 2006-2013 ($ MILLIONS)
• ANTIANDROGENS
  • TABLE 51 GLOBAL SALES OF ANTIANDROGENS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 28 GLOBAL SALES OF ANTIANDROGENS, 2006-2013 ($ MILLIONS)
• AROMATASE INHIBITORS
  • TABLE 52 GLOBAL SALES OF AROMATASE INHIBITORS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 29 GLOBAL SALES OF AROMATASE INHIBITORS, 2006-2013 ($ MILLIONS)
• LH-RH AGONISTS
  • TABLE 53 GLOBAL SALES OF LH-RH AGONISTS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 30 GLOBAL SALES OF LH-RH AGONISTS, 2006-2013 ($ MILLIONS)
• TARGET THERAPIES
• Market Size
  • TABLE 54 GLOBAL SALES OF TARGET THERAPY CANCER PRODUCTS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 31 WORLDWIDE SALES OF TARGET THERAPY CANCER PRODUCTS, 2006-2013 ($ MILLIONS)
  • TABLE 55 GLOBAL SHARE OF TARGETED THERAPY, BY TYPE, 2007 (%)
  • FIGURE 32 GLOBAL SHARE OF TARGET THERAPY, BY TYPE, 2007 (%)
• MONOCLONAL ANTIBODIES
  • TABLE 56 GLOBAL SALES OF MONOCLONAL ANTIBODIES, THROUGH 2013 ($ MILLIONS)
  • FIGURE 33 GLOBAL SALES OF MONOCLONAL ANTIBODIES, 2006-2013 ($ MILLIONS)
• SMALL MOLECULES
  • TABLE 57 GLOBAL SALES OF SMALL MOLECULES, THROUGH 2013 ($ MILLIONS)
  • FIGURE 34 GLOBAL SALES OF SMALL MOLECULES, 2006-2013 ($ MILLIONS)
• IMMUNOTHERAPY
• Market Size
  • TABLE 58 GLOBAL SALES OF IMMUNOTHERAPY PRODUCTS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 35 WORLDWIDE SALES OF IMMUNOTHERAPY PRODUCTS, 2006-2013 ($ MILLIONS)
  • TABLE 59 GLOBAL REVENUE SHARE OF IMMUNOTHERAPY BY TYPE, 2007 (%)
  • FIGURE 36 GLOBAL SHARE OF IMMUNOTHERPY, BY TYPE, 2007 (%)
• INTERFERONS AND CYTOKINES
  • TABLE 60 GLOBAL SALES OF INTERFERONS AND CYTOKINES, THROUGH 2013 ($ MILLIONS)
  • FIGURE 37 GLOBAL SALES OF INTERFERONS AND CYTOKINES, 2006-2013 ($ MILLIONS)
• VACCINES
  • TABLE 61 GLOBAL SALES OF CANCER VACCINES, THROUGH 2013 ($ MILLIONS)
  • FIGURE 38 GLOBAL SALES OF CANCER VACCINES, 2006-2013 ($ MILLIONS)

Chapter- 8: NEW DEVELOPMENTS

• NEW DEVELOPMENTS
  • TABLE 62 CANCER DRUG PIPELINE IN PHASE III CLINICAL TRIALS
  • TABLE 62 (CONTINUED)
  • TABLE 62 (CONTINUED)
  • TABLE 62 (CONTINUED)
• TARGET
  • TABLE 63 CANCER DRUG PIPELINE IN PHASE II CLINICAL TRIALS
  • TABLE 63 (CONTINUED)
  • TABLE 63 (CONTINUED)
  • TABLE 63 (CONTINUED)
  • TABLE 64 CANCER DRUG PIPELINE IN PHASE I CLINICAL TRIALS
  • TABLE 64 (CONTINUED)
  • TABLE 64 (CONTINUED)

Chapter- 9: MARKET BY DISEASE TYPE

• TABLE 65 GLOBAL SALES OF CANCER THERAPY BY TYPE OF CANCER, THROUGH 2013 ($ MILLIONS)
• FIGURE 39 GLOBAL SALES OF CANCER THERAPY BY TYPE OF CANCER, 2006-2013 ($ MILLIONS)
• TABLE 66 MARKET SHARE OF VARIOUS TYPES OF CANCER, 2007 (%)
• FIGURE 40 MARKET SHARE OF VARIOUS TYPES OF CANCER, 2007 (%)
• BREAST CANCER THERAPY
  • TABLE 67 SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN BREAST CANCER TREATMENT, 2007 ($ MILLION/%)
  • FIGURE 41 SALES OF VARIOUS THERAPIES USED IN BREAST CANCER TREATMENT, 2007 ($ MILLIONS)
  • TABLE 68 WORLDWIDE MARKET SHARE OF COMPANIES FOR BREAST CANCER THERAPY REVENUE, 2007 (%)
  • FIGURE 42 WORLDWIDE MARKET SHARE OF COMPANIES FOR BREAST CANCER THERAPY REVENUE, 2007 (%)
• COLORECTAL CANCER
  • TABLE 69 SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN COLORECTAL CANCER TREATMENT, 2007 ($ MILLION/%)
  • FIGURE 43 SALES OF VARIOUS THERAPIES USED IN COLORECTAL CANCER TREATMENT, 2007 ($ MILLIONS)
  • TABLE 70 WORLDWIDE MARKET SHARE OF COMPANIES IN COLORECTAL CANCER THERAPY REVENUE, 2007 (%)
  • FIGURE 44 WORLDWIDE MARKET SHARE OF COMPANIES IN COLORECTAL CANCER THERAPY REVENUE, 2007 (%)
• PROSTATE CANCER
  • TABLE 71 SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN PROSTATE CANCER TREATMENT, 2007 ($ MILLION/%)
  • FIGURE 45 SALES OF VARIOUS THERAPIES USED IN PROSTATE CANCER TREATMENT, 2007 ($ MILLIONS)
  • TABLE 72 WORLDWIDE MARKET SHARE OF COMPANIES IN PROSTATE CANCER THERAPY REVENUE, 2007 (%)
  • FIGURE 46 WORLDWIDE MARKET SHARE OF COMPANIES IN PROSTATE CANCER THERAPY REVENUE, 2007 (%)
• NONSMALL CELL LUNG CANCER
  • TABLE 73 GLOBAL SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN NONSMALL CELL LUNG CANCER TREATMENT, 2007 ($ MILLIONS/%)
  • FIGURE 47 GLOBAL SALES OF VARIOUS THERAPIES USED IN NONSMALL CELL LUNG CANCER TREATMENT, 2007 ($ MILLIONS)
  • TABLE 74 GLOBAL MARKET SHARE OF COMPANIES IN NON SMALL CELL LUNG CANCER THERAPY REVENUE, 2007 (%)
  • FIGURE 48 WORLDWIDE MARKET SHARE OF COMPANIES IN NON SMALL CELL LUNG CANCER THERAPY REVENUE, 2007 (%)
• HEAD AND NECK CANCER
  • TABLE 75 GLOBAL SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN HEAD AND NECK CANCER TREATMENT, 2007 ($ MILLION/%)
  • FIGURE 49 GLOBAL SALES OF VARIOUS THERAPIES USED IN HEAD AND NECK CANCER TREATMENT, 2007 ($ MILLIONS)
  • TABLE 76 WORLDWIDE MARKET SHARE OF COMPANIES IN HEAD AND NECK CANCER THERAPY REVENUE, 2007 (%)
  • FIGURE 50 WORLDWIDE MARKET SHARE OF COMPANIES IN HEAD AND NECK CANCER THERAPY REVENUE, 2007 (%)
• RENAL CELL CARCINOMA
  • TABLE 77 GLOBAL SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN RENAL CELL CARCINOMA TREATMENT, 2007 ($ MILLIONS/%)
  • FIGURE 51 GLOBAL SALES OF VARIOUS THERAPIES USED IN RENAL CELL CARCINOMA TREATMENT, 2007 ($ MILLIONS)
  • TABLE 78 GLOBAL MARKET SHARE OF COMPANIES IN RENAL CELL CARCINOMA THERAPY REVENUE, 2007 (%)
  • FIGURE 52 GLOBAL MARKET SHARE OF COMPANIES IN RENAL CELL CARCINOMA THERAPY REVENUE, 2007 (%)
• PANCREATIC CANCER THERAPY
  • TABLE 79 GLOBAL SALES AND MARKET SHARE OF VARIOUS THERAPIES USED IN PANCREATIC CANCER TREATMENT, 2007 ($ MILLION/%)
  • FIGURE 53 GLOBAL SALES OF VARIOUS THERAPIES USED IN PANCREATIC CANCER TREATMENT, 2007 ($ MILLIONS)
  • TABLE 80 GLOBAL MARKET SHARE OF COMPANIES IN PANCREATIC CANCER THERAPY REVENUE, 2007 (%)
  • FIGURE 54 GLOBAL MARKET SHARE OF COMPANIES IN PANCREATIC CANCER THERAPY REVENUE, 2007 (%)

Chapter- 10: PATENT ANALYSIS

• TOTAL PATENTS
• PATENTS BY YEAR
  • TABLE 81 TOTAL NUMBER OF PATENTS IN EACH YEAR, 2005-2008
  • FIGURE 55 NUMBER OF PATENTS, 2005-2008
• PATENTS BY TYPE
  • TABLE 82 NUMBER OF PATENTS BY TYPE, 2005-2008
  • FIGURE 56 NUMBER OF PATENTS BY TYPE, 2005-2008 (NO. OF PATENTS)
  • FIGURE 57 NUMBER OF PATENTS, SHARE BY TYPE, 2005-2008 (%)
• PATENTS BY COUNTRY
  • TABLE 83 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2008
  • TABLE 83 (CONTINUED)
• PATENTS BY COMPANY
  • TABLE 84 NUMBER OF PATENTS BY COMPANY, 2005-2008
  • TABLE 84 (CONTINUED)
  • TABLE 84 (CONTINUED)
• PATENTS BY ASSIGNEE
  • TABLE 85 NUMBER OF PATENTS BY ASIGNEE, 2005-2008

Chapter- 11: COMPANY PROFILES

• ABRAXIS BIOSCIENCES, INC.
• AMGEN INC.
• ASTRAZENECA PLC
• BIOGEN IDEC
• BRISTOL-MYERS SQUIBB
• CELGENE CORP.
• CEPHALON INC.
• CHUGAI PHARMACEUTICAL CO., LTD.
• ELI LILLY AND CO.
• GENENTECH INC.
• GENENTECH INC. (CONTINUED)
• GENZYME CORP.
• GLAXOSMITHKLINE PLC
• GPC BIOTECH AG
• IMCLONE SYSTEMS, INC.
• INFINITY PHARMACEUTICALS, INC.
• MERCK & CO.
• NOVARTIS
• OSI PHARMACEUTICALS, INC.
• PFIZER INC.
• PROGEN PHARMACEUTICALS, LTD.
• ROCHE
• SANOFI-AVENTIS
• SCHERING-PLOUGH
• SEATTLE GENETICS, INC.
• TAP PHARMACEUTICAL PRODUCTS, INC.
• TAIHO PHARMACEUTICALS CO., LTD.
• WYETH
• YM BIOSCIENCES, INC.

Chapter- 12: APPENDIX

• APPENDIX
• APPENDIX (CONTINUED)